Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine in Relapsed/Refractory Neuroblastoma
jRCT2031200270Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of LY3295668 in neuroblastoma (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Limiting Toxicities (DLTs), Overall Response Rate (ORR) and 1 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
LY3295668
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2031200270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200270.